ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol

How Lipoic Acid Preserves Critical Mitochondrial Function

New Option For Chronic Fatigue Syndrome

Living Longer, Healthier Lives with Resveratrol

Iodine: The Forgotten Medicine

Lipoic Acid Reverses Mitochondrial Decay

Stop Bacteria With Nature's Antibiotics

Nutraceutical Update - Rhodiola

New Test Shows Promise in Identifying New Drugs to Treat Lyme Disease

Coenzyme Q10 Helps Veterans Battle Gulf War Illness Symptoms

 
Print Page
Email Article

FDA Approves Pfizer Antifungal Medicine Vfend(R) (voriconazole)

  [ 119 votes ]   [ Discuss This Article ]
www.ProHealth.com • May 29, 2002





New drug expands options for treatment of life-threatening fungal infections

NEW YORK, May 28 /PRNewswire-FirstCall/ -- Pfizer Inc said today that the
U.S. Food and Drug Administration has given marketing clearance for both oral
and intravenous formulations of Vfend(R) (voriconazole) for the treatment of
deadly fungal infections.

Vfend is indicated for primary treatment of acute invasive aspergillosis
and salvage therapy for rare but serious fungal infections caused by the
pathogens Scedosporium apiospermum and Fusarium spp. In the largest clinical
trial of its kind, Vfend demonstrated superior efficacy and a survival benefit
versus the current treatment standard, amphotericin B, for primary treatment
of invasive aspergillosis, a deadly fungal infection occurring in immune
compromised patients.

The number of patients at risk for serious fungal infections is growing as
more patients undergo bone marrow and solid organ transplants as well as
aggressive chemotherapy for cancer. Fungal infections in these immunosuppressed patients are associated with high morbidity and mortality and
require prompt and effective treatment.

Vfend was discovered by Pfizer researchers in Sandwich, England and was
developed to address the unmet medical need for more effective and
better-tolerated options for patients with invasive aspergillosis and other
serious fungal infections.

Results from the largest prospective comparative clinical trial in
invasive aspergillosis ever conducted showed that 53 percent of patients who
received Vfend had a successful response at 12 weeks of treatment, compared to
32 percent of those who received amphotericin B. The survival rate of the
Vfend-treated patients was 71 percent versus 58 percent of those in the
amphotericin B arm of the study.

Vfend can be administered both orally and intravenously, unlike most
current available treatments. This allows for flexibility in patient care
with Vfend, permitting step-down therapy, an important consideration when
treating invasive fungal infections.

The most common side effects reported among Vfend patients were visual
disturbances, elevations of liver function tests and skin rash. These were
generally mild to moderate in severity and usually did not result in
discontinuation of treatment.

Pfizer said Vfend will be available in hospitals this summer.

Pfizer Inc discovers, develops, manufactures and markets leading
prescription medicines, for humans and animals, and many of the world's
best-known consumer products.

Full prescribing information is available upon request, or at
http://www.pfizer.com.



Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Immune Support Supplements

Featured Products

Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders
The Brain Boosting and Fatigue Fighting B-12 The Brain Boosting and Fatigue Fighting B-12
The Curcumin Revolution: The Curcumin Revolution: "Golden" Ticket to Better Health
VIDEO: Healthy Eating and Fibromyalgia VIDEO: Healthy Eating and Fibromyalgia
Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing